Li Z, Jing X, Yuan Y, Shui Y, Li S, Zhao Z
Front Microbiol. 2022; 13:862834.
PMID: 35633688
PMC: 9130856.
DOI: 10.3389/fmicb.2022.862834.
Eom K, Li S, Lee E, Kim J, Kim J, Kim I
Polymers (Basel). 2022; 14(9).
PMID: 35567037
PMC: 9104764.
DOI: 10.3390/polym14091868.
Deslouches B, Montelaro R, Urish K, Di Y
Pharmaceutics. 2020; 12(6).
PMID: 32486228
PMC: 7357155.
DOI: 10.3390/pharmaceutics12060501.
Jiang S, Deslouches B, Chen C, Di M, Di Y
mBio. 2019; 10(2).
PMID: 30967458
PMC: 6456746.
DOI: 10.1128/mBio.00226-19.
Lashua L, Melvin J, Deslouches B, Pilewski J, Montelaro R, Bomberger J
J Antimicrob Chemother. 2016; 71(8):2200-7.
PMID: 27231279
PMC: 4954927.
DOI: 10.1093/jac/dkw143.
Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine.
Deslouches B, Hasek M, Craigo J, Steckbeck J, Montelaro R
J Med Microbiol. 2016; 65(6):554-565.
PMID: 27046192
PMC: 5042116.
DOI: 10.1099/jmm.0.000258.
Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.
Mandal S, Roy A, Ghosh A, Hazra T, Basak A, Franco O
Front Pharmacol. 2014; 5:105.
PMID: 24860506
PMC: 4027024.
DOI: 10.3389/fphar.2014.00105.
Hp1404, a new antimicrobial peptide from the scorpion Heterometrus petersii.
Li Z, Xu X, Meng L, Zhang Q, Cao L, Li W
PLoS One. 2014; 9(5):e97539.
PMID: 24826994
PMC: 4020842.
DOI: 10.1371/journal.pone.0097539.
Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2.
Paranjape S, Lauer T, Montelaro R, Mietzner T, Vij N
F1000Res. 2014; 2:36.
PMID: 24555033
PMC: 3894802.
DOI: 10.12688/f1000research.2-36.v1.
Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens.
Deslouches B, Steckbeck J, Craigo J, Doi Y, Mietzner T, Montelaro R
Antimicrob Agents Chemother. 2013; 57(6):2511-21.
PMID: 23507278
PMC: 3716171.
DOI: 10.1128/AAC.02218-12.
Interaction of pneumococcal phase variation and middle ear pressure/gas composition: an in vitro model of simulated otitis media.
Li-Korotky H, Banks J, Lo C, Zeng F, Stolz D, Swarts J
Microb Pathog. 2008; 45(3):201-6.
PMID: 18619763
PMC: 2604118.
DOI: 10.1016/j.micpath.2008.05.004.
Cytopathic mechanisms of HIV-1.
Costin J
Virol J. 2007; 4:100.
PMID: 17945027
PMC: 2174939.
DOI: 10.1186/1743-422X-4-100.
De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia.
Deslouches B, Gonzalez I, DeAlmeida D, Islam K, Steele C, Montelaro R
J Antimicrob Chemother. 2007; 60(3):669-72.
PMID: 17623696
PMC: 3584960.
DOI: 10.1093/jac/dkm253.
Inactivation of herpes simplex virus clinical isolates by using a combination microbicide.
Isaacs C, Rohan L, Xu W, Jia J, Mietzner T, Hillier S
Antimicrob Agents Chemother. 2006; 50(3):1063-6.
PMID: 16495269
PMC: 1426429.
DOI: 10.1128/AAC.50.3.1063-1066.2006.
Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.
Deslouches B, Islam K, Craigo J, Paranjape S, Montelaro R, Mietzner T
Antimicrob Agents Chemother. 2005; 49(8):3208-16.
PMID: 16048927
PMC: 1196285.
DOI: 10.1128/AAC.49.8.3208-3216.2005.